Intuitive Surgical Inc. (ISRG) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Intuitive Surgical Inc. (ISRG)

405.61

-5.94 (1.44%)

as of Jul 10, 2026, 6:52:02 pm Market Open.

128 watching

Investor Insights

Jul 10, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Intuitive Surgical Inc. (ISRG-Q) is facing a challenging environment characterized by an overall decline in the med tech sector, although there remains potential for long-term growth in robotic-assisted surgeries. While some experts express concern over recent earnings and forecasts from their Da Vinci business, others note the company's innovation in robotics and believe that the opportunities in this field will continue to expand. Analysts are divided; some are waiting for a more attractive entry point, while others observe that current pricing appears attractive despite the recent decline in stock value. The upcoming earnings report is anticipated with caution, as previous surprises may not be sustainable due to growing competition in the market. Overall, the company remains a subject of interest for long-term investors, especially if it can navigate its current challenges effectively.

Consensus

Cautious

Valuation

Fair Value

Similar

PNUX

HOLD

ISRG vs. SYK Reported last night, market not too happy, but this is short term. At 50x PE, expensive on any traditional valuation. Has no real competition in robotic surgery market. Great franchise and platform. Will grow earnings over next decade 200-300%. Because SYK is in hips and knees, it's not in direct competition. SYK's space is more competitive, but also has much lower valuation. With Covid shortages ending, SYK could see some upside next 3-4 months.

DON'T BUY

He's looked at it for 20 years. Their technological, Da Vinci, is a successful robotic surgical tool. But their PE is very high; people pay up for this technology, which has gone up and down (down during Covid when there were few surgeries). But shares have bounced back. PE remains too high. Pass.

WATCH

They make surgical robots. Their install base is growing, but their PE always been too high. They might change because shares have come off. Don't buy, but watch.

HOLD

He likes it and will stick by it, but the market isn't fond of this sector.

TOP PICK

Leader in robotic surgery. Relatively early days in this space, and ISRG has a massive head start. Both JNJ and MDT are trying to enter this market and having trouble. Recurring revenue model drives financial performance. Less invasive, new product for diagnosing lung tumours. Expensive PE, but highly profitable. He expects 10-15% growth of topline revenue for next decade. No dividend. (Analysts’ price target is $250.34)

PARTIAL BUY

Leader in robotic surgeries. More volatility due to concentration in that area. Still trades at 36x earnings. Solid growth franchise. Could be subject to M&A. He prefers a more diversified company. You could ladder into it.

BUY

Add to position? Yes, as Covid peaks, this stock will go back up though not much beyond its highs. This was hurt by lockdowns which halted surgeries.

STRONG BUY

Very well positioned in robotics surgery, the leader by far. Go-to name. More and more procedures will be performed by robots. Very bullish.

BUY

Great management and growth. He's a big fan.

PAST TOP PICK

(A Top Pick Aug 24/20, Up 18%) Leader in robotic surgery. Penetration is only about 5% right now, so lots of room to grow. Expensive, but very sure growth. Can hold it forever.

PAST TOP PICK

(A Top Pick Apr 17/20, Up 65%) Doctors are trained to use their system so competitors find it hard to get into the market. They are starting to reduce prices on some of their tools ahead of the coming competition. He will hold it for the foreseeable future.

BUY

Allan Tong’s Discover Picks I recommended this last August. As we face the reopening and eventual recovery, elective surgeries will bounce back and there will be a huge backlog to process. This backlog spells a boom for any company directly tied to surgeries. That’s short term. A longer-term tailwind for ISRG stock is the continued adoption of robotic surgery and this is where the automation stock shines bright. Robotic surgeries increased from 1.8% of all operations in 2012 to 15.1% in 2018. Read 3 Underestimated Automation Stocks for our full analysis.

PAST TOP PICK

(A Top Pick Jan 02/20, Up 27%) A great long-term play on robotically assisted surgery, a leader in this area. It's an expensive growth stock, but the outlook is so strong it's worth it. There's lots of room globally for surgery to adopt this technology.

BUY

Fractional shares to buy instead of playing the short squeeze of GameStop, AMC, etc. They make precision surgical machines which amazes him. Promising.

PAST TOP PICK

(A Top Pick Aug 19/19, Up 49%) A leader in robotic surgery. It provides a better surgical experience with more precise surgeries. The long-term story is that right now, robotic surgery accounts for 4% of surgeries right now. They have a huge head start in this domain and have great cashflow.

Showing 31 to 45 of 58 entries

Most Recent Experts

Darren Sissons

Campbell Lee & Ross

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rebecca Teltscher

Newhaven Asset Management

Ernest Wong, Head of Research, Baskin Wealth Management

Baskin Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Intuitive Surgical Inc. (ISRG)